Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
August 16, 2021 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces $100 Million Share Repurchase Program

STOUGHTON, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
August 05, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million

– Xtampza® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 – – Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million – – Full-Year 2021 Product Revenue...
July 21, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5,...
June 16, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Publication of Real-World Data in Journal of Pain Research

STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
May 20, 2021 16:05 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Participate in Upcoming Investor Conference

STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
May 06, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Record Quarterly Revenue of $87.7 Million

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta® Franchise and Adjusted EBITDA 2021 Guidance Range Raised – – Colleen Tupper Appointed...
April 15, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update

STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...
February 25, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million

– 2020 First Full-Year of Profitability, Driven by Xtampza® ER Revenue Growth and the Nucynta® Acquisition – – Collegium Reiterates Previously Issued 2021 Guidance – – Conference Call Scheduled for...
February 11, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update

STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...